These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 6949614)

  • 61. Long-term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous-infusion high-dose cytosine arabinoside.
    Ghaddar HM; Plunkett W; Kantarjian HM; Pierce S; Freireich EJ; Keating MJ; Estey EH
    Leukemia; 1994 Aug; 8(8):1269-74. PubMed ID: 8057660
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Separation of blast cell and T-lymphocyte progenitors in the blood of patients with acute myeloblastic leukemia.
    Minden MD; Buick RN; McCulloch EA
    Blood; 1979 Jul; 54(1):186-95. PubMed ID: 312670
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
    Gandhi V; Estey E; Du M; Nowak B; Keating MJ; Plunkett W
    Clin Cancer Res; 1995 Feb; 1(2):169-78. PubMed ID: 9815970
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Generation of reactive oxygen intermediates after treatment of blasts of acute myeloblastic leukemia with cytosine arabinoside: role of bcl-2.
    Hedley DW; McCulloch EA
    Leukemia; 1996 Jul; 10(7):1143-9. PubMed ID: 8683994
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Blast cell proliferative activity and sensitivity to GM-CSF in vitro are associated with early response to TAD-9 induction therapy in acute myeloid leukemia.
    Jahns-Streubel G; Reuter C; Unterhalt M; Schleyer E; Wörmann B; Büchner T; Hiddemann W
    Leukemia; 1995 Nov; 9(11):1857-63. PubMed ID: 7475275
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Low-dose cytosine arabinoside (LD-Ara C) treatment in dysmyelopoietic syndromes (DMPS) and acute myelogenous leukemia (AML).
    Jehn U; Göldel N; Vehling-Kaiser U
    Anticancer Res; 1987; 7(3 Pt B):505-8. PubMed ID: 3477124
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Post-remission therapy of adult acute myeloid leukemia: high dose cytosine-arabinoside versus other consolidation regimens.
    Zeremski V; Savić A
    Med Pregl; 2014; 67(3-4):83-90. PubMed ID: 24961049
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Hematopoietic growth factor stimulation and cytarabine cytotoxicity in vitro: effects in untreated and relapsed or primary refractory acute myeloid leukemia cells.
    te Boekhorst PA; Löwenberg B; Sonneveld P
    Leukemia; 1994 Sep; 8(9):1480-6. PubMed ID: 7522289
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effect of platelet-derived growth factor on the proliferation of blast progenitors from acute myeloblastic leukemia patients.
    Nara N; Tohda S; Nagata K; Suzuki T; Yamashita Y; Imai Y
    Acta Haematol; 1990; 83(4):187-92. PubMed ID: 2115715
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Association of genetic polymorphisms in genes involved in Ara-C and dNTP metabolism pathway with chemosensitivity and prognosis of adult acute myeloid leukemia (AML).
    Zhu KW; Chen P; Zhang DY; Yan H; Liu H; Cen LN; Liu YL; Cao S; Zhou G; Zeng H; Chen SP; Zhao XL; Chen XP
    J Transl Med; 2018 Apr; 16(1):90. PubMed ID: 29631596
    [TBL] [Abstract][Full Text] [Related]  

  • 71. FLAG-Ida Regimen as Bridge Therapy to Allotransplantation in Refractory/Relapsed Acute Myeloid Leukemia Patients.
    Delia M; Pastore D; Carluccio P; Pasciolla C; Ricco A; Rossi AR; Casieri P; Mestice A; Albano F; Specchia G
    Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):767-773. PubMed ID: 28864170
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Regulation of drug sensitivity by ribosomal protein S3a.
    Hu ZB; Minden MD; McCulloch EA; Stahl J
    Blood; 2000 Feb; 95(3):1047-55. PubMed ID: 10648421
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Correlation of drug sensitivity in vitro with clinical responses in childhood acute myeloid leukemia.
    Dow LW; Dahl GV; Kalwinsky DK; Mirro J; Nash MB; Roberson PK
    Blood; 1986 Aug; 68(2):400-5. PubMed ID: 3460647
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Mitoxantrone and cytosine arabinoside as treatment for acute myeloblastic leukemia in older patients.
    MacCallum PK; Rohatiner AZ; Davis CL; Whelan JS; Oza AM; Lim J; Love S; Amess JA; Leahy M; Gupta RK
    Ann Hematol; 1995 Jul; 71(1):35-9. PubMed ID: 7632817
    [TBL] [Abstract][Full Text] [Related]  

  • 75. High-dose cytarabine as salvage therapy for relapsed or refractory acute myeloid leukemia--is more better or more of the same?
    Wolach O; Itchaki G; Bar-Natan M; Yeshurun M; Ram R; Herscovici C; Shpilberg O; Douer D; Tallman MS; Raanani P
    Hematol Oncol; 2016 Mar; 34(1):28-35. PubMed ID: 25689584
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A real-world study of clofarabine and cytarabine combination therapy for patients with acute myeloid leukemia.
    He F; Sapkota S; Parker S; Defor T; Warlick E; Ustun C; Eckfeldt C; Rashidi A; Kurtzweil A; Weisdorf D; Bejanyan N
    Leuk Lymphoma; 2018 Oct; 59(10):2352-2359. PubMed ID: 29415603
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Pretreatment prognostic factors for overall survival in primary resistant acute myeloid leukemia.
    Colovic N; Tomin D; Vidovic A; Suvajdzic N; Jankovic G; Palibrk V; Djunic I; Djurasinovic V; Virijevic M
    Biomed Pharmacother; 2012 Dec; 66(8):578-82. PubMed ID: 23085253
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Effects of cytosine arabinoside on DNA synthesis as predictor for acute myelocytic leukemia (AML) patients' response to chemotherapy.
    Epstein J; Preisler H
    Eur J Cancer (1965); 1981 Jun; 17(6):623-8. PubMed ID: 6946929
    [No Abstract]   [Full Text] [Related]  

  • 79. Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome.
    Wu L; Li X; Su J; Chang C; He Q; Zhang X; Xu L; Song L; Pu Q
    Leuk Lymphoma; 2009 Sep; 50(9):1461-7. PubMed ID: 19672772
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Cytotoxic action of low dose Ara-C. Investigations in a marrow grafted patient with relapse.
    Mittermüller J; Kolb HJ; Gerhartz HH; Wilmanns W
    Onkologie; 1985 Jun; 8(3):168-71. PubMed ID: 3160990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.